Please ensure Javascript is enabled for purposes of website accessibility Global Life Sciences Fund - Janus Henderson Investors
For financial professionals in Uruguay

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE0009355771

NAV
USD 51.29
As of 2024/04/15

1-Day Change
USD -0.37 (-0.72%)
 As of 2024/04/15

Morningstar Rating

As of 2024/03/31

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.
Performance target: To outperform the MSCI World Health Care Index by at least 2% per annum, before the deduction of charges, over any 5 year period.

More

The Fund invests at least 80% in shares (also known as equities) of companies, of any size, including smaller capitalisation companies, with a life sciences orientation, in any country. Up to 20% may be invested in developing markets.
The Fund may also invest in other assets including cash and money market instruments.
The Sub-Investment Adviser may use derivatives (complex financial instruments) to reduce risk, to manage the Fund more efficiently, or to generate additional capital or income for the Fund.
The Fund is actively managed with reference to the MSCI World Health Care Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target. The Sub-Investment Adviser has discretion to choose individual investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.

Less

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.
Potential investors must read the prospectus, and where relevant, the key investor information document before investing.
This website is a Marketing Communication and does not qualify as an investment recommendation.

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care
Past performance does not predict future returns. 
 

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Past performance does not predict future returns. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
Cumulative & Annualised Performance (%)
As of 2024/03/31
A2 USD (Net) MSCI World Health Care NR
  
  Cumulative Annualised
1MO YTD 1YR 3YR 5YR 10YR Since Inception
2000/03/31
A2 USD (Net) 1.56 8.07 15.99 5.68 9.56 9.50 7.33
MSCI World Health Care NR 2.35 7.47 13.32 7.85 10.33 9.18 7.79
 
  Annualised
3YR 5YR 10YR Since Inception
2000/03/31
A2 USD (Gross) - 12.17 12.14 10.10
MSCI World Health Care NR + 2.00% - 12.53 11.37 9.94
Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk.  Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations.
Performance/performance target related data will display only when relevant to the fund/share class inception date and the annualised target time period.
© Morningstar 2024. All rights reserved. NAV-NAV, gross income reinvested where applicable.
Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time.
The ongoing charges includes fees payable to Distributors. Where the ongoing charges exceed the target outperformance relative to the benchmark the return is likely to be below the benchmark return, even when the Fund’s outperformance target (before the deduction of charges) has been achieved.
Calendar Year Returns (%)
As of 2024/03/31
A2 USD (Net) MSCI World Health Care NR
YTD 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
A2 USD (Net) 8.07 5.44 -4.35 4.72 23.41 27.06 2.01 20.55 -13.79 5.69 32.75
MSCI World Health Care NR 7.47 3.76 -5.41 19.80 13.52 23.24 2.51 19.80 -6.81 6.60 18.10
Calendar Year Returns (%)
Year A2 USD (Net) Index
2023 5.44 3.76
2022 -4.35 -5.41
2021 4.72 19.80
2020 23.41 13.52
2019 27.06 23.24
2018 2.01 2.51
2017 20.55 19.80
2016 -13.79 -6.81
2015 5.69 6.60
2014 32.75 18.10
2013 52.45 36.27
2012 22.47 17.54
2011 6.08 9.46
2010 6.04 2.41
2009 24.46 18.89
2008 -31.08 -21.50
2007 19.64 3.94
2006 -3.74 10.47
2005 9.89 9.00
2004 12.36 6.00
2003 25.55 19.50
2002 -31.32 -17.98
2001 -20.46 -13.24
2000 from 31/03/2000 16.80 25.65
Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk.  Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations.
Performance/performance target related data will display only when relevant to the fund/share class inception date and the annualised target time period.
© Morningstar 2024. All rights reserved. NAV-NAV, gross income reinvested where applicable.
Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time.
The ongoing charges includes fees payable to Distributors. Where the ongoing charges exceed the target outperformance relative to the benchmark the return is likely to be below the benchmark return, even when the Fund’s outperformance target (before the deduction of charges) has been achieved.
FEE INFORMATION
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2022/12/31) 		2.40%
The ongoing charge is calculated using the PRIIPs methodology. The PRIIPs methodology differs to the UCITS ongoing charge methodology, as the PRIIPS methodology captures additional recurring charges, including but not limited to: a. Interest paid on borrowing (e.g. bank interest) b. Any fees incurred in relation to stock-lending activity (i.e. the fee paid to the lending agent) c. Any costs associated with holding closed-ended vehicles.
For more information about charges, please see our fund charges page or the “charges” section of the fund’s prospectus.

Portfolio

Top Holdings (As of 2024/03/31)
% OF FUND
Eli Lilly & Co 7.08
UnitedHealth Group Inc 5.87
Novo Nordisk A/S 5.13
Merck & Co Inc 3.64
AstraZeneca PLC 3.57
AbbVie Inc 3.36
Sanofi SA 2.48
Boston Scientific Corp 2.30
Vertex Pharmaceuticals Inc 2.30
Abbott Laboratories 2.26
TOTAL 37.99
References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.
Sector Allocation % OF FUND % OF FUND (As of 2024/03/31)
Regional Allocation % OF FUND % OF FUND (As of March 31, 2024)

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
Why healthcare stocks could catch a break this election year
Apr 2, 2024
Timely & Topical

Why healthcare stocks could catch a break this election year

The sector has historically underperformed in the lead-up to U.S. presidential elections, but that may not be the case in 2024.

5 min read

Global Perspectives: Investing in the small- and midsize healthcare companies innovating for a graying world
Feb 21, 2024
Features & Outlooks

Global Perspectives: Investing in the small- and midsize healthcare companies innovating for a graying world

How healthcare’s small- and mid-cap companies could benefit from one of today’s key macroeconomic growth drivers: aging populations.

27 min read

Healthcare’s small- and mid-cap opportunities amid aging populations
Feb 13, 2024
Features & Outlooks

Healthcare’s small- and mid-cap opportunities amid aging populations

With populations in some of the largest economies quickly graying, innovative small- and mid-cap healthcare companies could deliver new growth opportunities for investors.

8 min read

  • The value of the Funds and the income from them is not guaranteed and may fall as well as rise. You may get back less than you originally invested.
  • Past performance does not predict future returns.
  • Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.
  • Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates.
  • When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies.
  • Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
  • The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.
  • Funds incur costs as a necessary part of buying and selling the underlying investments, these are otherwise known as portfolio transaction costs, and include charges such as broker commission and Stamp Duty.
  • Before investing in any of our funds you should satisfy yourself as to the suitability and the risks involved.
  • Summary of Investor rights
  • Janus Henderson Investors Europe S.A. may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation.
  • Information on compliance with EU Sustainability related disclosures can be found here.
  • For detailed product information including the risks associated with investing please read the relevant Prospectus or Annual Report. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.